<WIRE> Positive Pre-Clinical Trial Results on Cimetra Announced by MGC Pharmaceuticals (ASX:MXC)

Monday, 14 August 2023

MGC Pharmaceuticals (ASX:MXC) has announced positive pre-clinical trial results on Cimetra.

The company reported favorable findings from its pre-clinical chronic toxicology evaluation of a 14-day oral dose of Cimetra.

Further, post a full chronic safety and toxicology analysis of Cimetra in large animals, the drug was found to be safe.

The company has planned to submit an IND (Investigational New Drug) application for Cimetra in the first quarter of 2024.

Supported by

<SPON> Trade share CFDs with Plus500

Apr 4, 2022

Global online trading services company, Plus500:

Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.

Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.

LINK

Subscribe to the newsletter

Receive whispers every day in your inbox.